Return to Contents in this Issue

Guidelines
 

Hypersensitivity Reactions to Blood Components: Document Issued by the Allergy Committee of the French Medicines and Healthcare Products Regulatory Agency
 

PM Mertes,1 A Bazin,2 F Alla,3 J Bienvenu,4 C Caldani,5 B Lamy,6 D Laroche,7 MF Leconte des Floris,8 J-Y Py,9 D Rebibo,10 B Willaert,11 P Demoly12

1Service d’Anesthésie-Réanimation, INSERM U961, Hôpital Central, CHU, Nancy, France
2Unité Hémovigilance, CHU Côte de Nacre, Caen, France
3Centre d’investigation clinique - Epidémiologie clinique, Inserm, Centre Hospitalier Universitaire de Nancy, Nancy, France
4Centre de Biologie Sud, Inserm U851, Université Lyon, Pierre Bénite, France
5Afssaps, DEMEB/Unité Hémovigilance, Saint Denis, France
6Agence Régionale de Santé de Bourgogne, Dijon, France
7Laboratoire de Biophysique, CHU Côte de Nacre, France
8Etablissement Français du Sang, Besançon, France
9Etablissement Français du Sang Centre Atlantique, Orléans, France
10Direction Médicale, Etablissement Français du Sang, La Plaine Saint Denis, France
11Afssaps, DEMEB/Unité Hémovigilance, Saint Denis, France
12Service de Pneumologie et Allergologie, INSERM U657, Hôpital Arnaud de Villeneuve, CHU, Montpellier, France

J Investig Allergol Clin Immunol 2011; Vol. 21(3): 171-178
 

 Abstract


These guidelines represent a consensus among experts on hypersensitivity reactions occurring after transfusion of blood components. They
cover recognition, investigation, treatment, and prevention of such reactions. Implemented in France under the auspices of the French
Medicines and Healthcare Products Regulatory Agency (AFSSAPS) and based on current knowledge, research, and experience, they aim to
provide effective and easily teachable means of further improving the quality of hemovigilance databases, promote interest in this field,
and help identify possible mechanisms and at-risk patient groups.

Key words: Anaphylaxis. Blood component. Diagnosis procedure. Hypersensitivity.